Get the Stockscreener App
2.37
8.72%
0.19
After Hours:
2.35
-0.02
-0.84%
Xortx Therapeutics Inc stock is traded at $2.37, with a volume of 33,669.
It is up +8.72% in the last 24 hours and down -21.78% over the past month.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
See More
Previous Close:
$2.18
Open:
$2.3
24h Volume:
33,669
Relative Volume:
0.03
Market Cap:
$4.10M
Revenue:
-
Net Income/Loss:
$-2.66M
P/E Ratio:
-0.7898
EPS:
-3.0006
Net Cash Flow:
$-2.83M
1W Performance:
+2.16%
1M Performance:
-21.78%
6M Performance:
-23.92%
1Y Performance:
-50.16%
1-Day Range:
$2.192
$2.72
1-Week Range:
$2.07
$2.72
52-Week Range:
$1.725
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
2.37 | 3.77M | 0 | -2.66M | -2.83M | -3.0006 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
XRTX Stock Chart | XORTX THERAPEUTICS INC (NASDAQ:XRTX) - ChartMill
XORTX Therapeutics Q1 2024 Earnings: Steep EPS Miss Highlights Pre‑Revenue Biotech HurdlesEarnings Recovery Stocks - Newser
XORTX Therapeutics Raises US$5 Million Via Public Offering - marketscreener.com
XORTX Announces Closing of US$5 Million Public Offering - markets.businessinsider.com
XORTX Therapeutics (NASDAQ: XRTX) closes US$5M share and pre-funded warrant deal - Stock Titan
XORTX raises US$5M, earmarks US$2.5M for investor marketing - Stock Titan
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering - The Manila Times
XORTX (NASDAQ: XRTX) posts Q1 2026 loss, adds VB4-P5 asset and launches $5M equity raise - Stock Titan
XORTX Therapeutics Inc.Common Shares (NQ: XRTX - FinancialContent
XORTX Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
XORTX Therapeutics Inc expected to post a loss of C$1.64 a shareEarnings Preview - TradingView
Here are the top movers in Friday's session. - ChartMill
XORTX (NASDAQ: XRTX) raises ~$4.7M via share sale and pre-funded warrants - Stock Titan
XRTX Announces Public Offering of Shares - GuruFocus
XORTX Therapeutics Raising US$5 Million in a Public Offering; Shares Down 8.9% - marketscreener.com
XORTX (NASDAQ: XRTX) prices US$5M public equity and warrant deal - Stock Titan
Xortx announces US$5 million public offering - marketscreener.com
XORTX Announces US$5 Million Public Offering - The Manila Times
XORTX Announces US$5 Million Public Offering | Associated Press | syndication news - Enidnews.com
[EFFECT] XORTX Therapeutics Inc. SEC Filing - Stock Titan
Kidney drug developer XORTX prices US$5M Nasdaq share sale - Stock Titan
XORTX Says Preliminary Equity Levels Meet Nasdaq Listing Threshold - The Globe and Mail
XORTX (NASDAQ: XRTX) estimates $4.1M equity, above Nasdaq minimum - Stock Titan
1.8M-share offering — XORTX Therapeutics (NASDAQ: XRTX) files F-1 amendment - Stock Titan
XRTX XORTX Therapeutics posts far wider Q1 2024 loss than estimates, shares fall 1.85% amid elevated RD spending.Balance Sheet - newser.com
XORTX shareholders approve up-to-5-for-1 share consolidation to meet Nasdaq rules - MSN
XORTX Therapeutics (XRTX) Stock: Pricing Efficiency Review | Q1 2024: Earnings Fall ShortAnalyst Recommended Stocks - Newser
XORTX Therapeutics (NASDAQ: XRTX) registers up to 2.2M shares; $4.7M estimated proceeds - Stock Titan
XORTX Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
XORTX Regains Nasdaq Listing Compliance After Reverse Stock Split - The Globe and Mail
XORTX Therapeutics (NASDAQ: XRTX) files F-1: 2.2M shares, pre-funded warrants - Stock Titan
XRTX SEC FilingsXortx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
XRTX Stock Jumps As VB4-P5 Kidney Deal Expands Pipeline - StocksToTrade
XRTX Stock Jumps As Kidney Pipeline Expands With VB4-P5 Deal - StocksToTrade
XORTX Therapeutics jumps as it confirms Nasdaq bid-price compliance after reverse split - Quiver Quantitative
XORTX (NASDAQ: XRTX) cures Nasdaq minimum bid deficiency - Stock Titan
XRTX Jumps As New Kidney Fibrosis Deal Expands Pipeline - timothysykes.com
XORTX Therapeutics Says Met Nasdaq Continued Listing Requirements - marketscreener.com
XORTX Meets Nasdaq Continued Listing Requirements - GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday SessionFirefly Neuroscience (NASDAQ:AIFF), AIxCrypt - Benzinga
XORTX Therapeutics (XRTX) Stock: Insider Signals (Smart Money Outflows) 2026-04-20Certified Trade Ideas - Newser
XORTX (NASDAQ: XRTX) closes $3M VB4-P5 kidney anti-fibrotic deal - Stock Titan
Discontinued operations of XORTX Therapeutics, Inc. – DUS:ANU - TradingView — Track All Markets
Long term debt to total equity ratio of XORTX Therapeutics, Inc. – DUS:ANU - TradingView
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):